ALMS (Alumis) FCF Yield % : -83.69 (As of Mar. 30, 2025)

View and export this data going back to 2024. Start your Free Trial

What is Alumis FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Alumis's Trailing 12-Month Free Cash Flow is $-256.81 Mil, and Market Cap is $306.86 Mil. Therefore, Alumis's FCF Yield % for today is -83.69%.

The historical rank and industry rank for Alumis's FCF Yield % or its related term are showing as below:

ALMS' s FCF Yield % Range Over the Past 10 Years
Min: -83.69 Med: 0 Max: 0
Current: -83.69

ALMS's FCF Yield % is ranked worse than
81.03% of 1502 companies
in the Biotechnology industry
Industry Median: -14.915 vs ALMS: -83.69

Alumis's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

Alumis FCF Yield % Historical Data

The historical data trend for Alumis's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alumis FCF Yield % Chart

Alumis Annual Data

Trend

Dec22

Dec23

Dec24

FCF Yield %

-60.05

Alumis Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Yield %	Get a 7-Day Free Trial				-	-	-29.17	-58.20	-70.27

Competitive Comparison of Alumis's FCF Yield %

For the Biotechnology subindustry, Alumis's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alumis's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alumis's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Alumis's FCF Yield % falls into.

Save Embed

;

Save Embed

;

Alumis FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Alumis's FCF Yield % for the fiscal year that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-256.81	/	427.63902
	=	-60.05%

Alumis's annualized FCF Yield % for the quarter that ended in Dec. 2024 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-75.13	*	4	/	427.63902
	=	-70.27%

Alumis FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Alumis FCF Yield % Related Terms

Thank you for viewing the detailed overview of Alumis's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Alumis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alumis Inc (NAS:ALMS) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

280 East Grand Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alumis.com

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.